Ascendis Pharma AS (A71) - Total Liabilities

Latest as of December 2025: €1.47 Billion EUR ≈ $1.71 Billion USD

Based on the latest financial reports, Ascendis Pharma AS (A71) has total liabilities worth €1.47 Billion EUR (≈ $1.71 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Ascendis Pharma AS generate cash to assess how effectively this company generates cash.

Ascendis Pharma AS - Total Liabilities Trend (2016–2025)

This chart illustrates how Ascendis Pharma AS's total liabilities have evolved over time, based on quarterly financial data. Check Ascendis Pharma AS liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Ascendis Pharma AS Competitors by Total Liabilities

The table below lists competitors of Ascendis Pharma AS ranked by their total liabilities.

Company	Country	Total Liabilities
Focus Media Information Technology Co Ltd SHE:002027	China	CN¥6.96 Billion
Bharat Heavy Electricals Limited NSE:BHEL	India	Rs475.72 Billion
ARC Resources Ltd. TO:ARX	Canada	CA$5.88 Billion
Toll Brothers Inc NYSE:TOL	USA	$6.01 Billion
YPF Sociedad Anónima F:YPF	Germany	€17.93 Billion
The Siam Commercial Bank Public Company Limited BK:SCB-R	Thailand	฿3.02 Trillion
Sociedad Química y Minera de Chile S.A. SN:SQM-B	Chile	CL$6.19 Billion

Liability Composition Analysis (2016–2025)

This chart breaks down Ascendis Pharma AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Ascendis Pharma AS.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.04	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	-9.00	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	1.12	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Ascendis Pharma AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Ascendis Pharma AS (2016–2025)

The table below shows the annual total liabilities of Ascendis Pharma AS from 2016 to 2025.

Year	Total Liabilities	Change
2025-12-31	€1.47 Billion ≈ $1.71 Billion	+14.02%
2024-12-31	€1.29 Billion ≈ $1.50 Billion	+32.32%
2023-12-31	€971.28 Million ≈ $1.14 Billion	+17.53%
2022-12-31	€826.39 Million ≈ $966.14 Million	+310.56%
2021-12-31	€201.29 Million ≈ $235.32 Million	+42.67%
2020-12-31	€141.08 Million ≈ $164.94 Million	+77.20%
2019-12-31	€79.62 Million ≈ $93.08 Million	+104.58%
2018-12-31	€38.92 Million ≈ $45.50 Million	+63.74%
2017-12-31	€23.77 Million ≈ $27.79 Million	+76.61%
2016-12-31	€13.46 Million ≈ $15.73 Million	--

About Ascendis Pharma AS

F:A71 Germany Biotechnology

Market Cap

$14.79 Billion

€12.65 Billion EUR

Market Cap Rank

#1779 Global

#380 in Germany

Share Price

€206.00

Change (1 day)

+0.98%

52-Week Range

€170.00 - €210.00

All Time High

€210.00